Bitcoin parabola breakdown raises chance for 80% correction: Veteran trader

A veteran trader warned that Bitcoin’s parabola breakdown could be followed by an 80% price correction. Will history repeat ...
pharmaphorum

FDA fast tracks type 1 diabetes cell therapy from Vertex

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based therapy ...
The Motley Fool

Where Will Vertex Pharmaceuticals Be in 5 Years

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
The Boston Globe

Vertex’s CEO was an AI skeptic. But not anymore.

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...
STAT

Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Benzinga.com

Vertex CEO David DeStefano Steps Down After 26 Years

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...
Seeking Alpha

Vertex Pharmaceuticals: I'm Downgrading To Hold On Drug Pricing, Pipeline Concerns

Vertex Pharmaceuticals Incorporated is downgraded from Buy to Hold due to mounting headwinds and pipeline uncertainties. Vertex faces pressure from potential U.S. drug pricing reforms and tariffs, ...
FiercePharma

Vertex narrows near-term development plan for Journavx after FDA naysays broad label in neuropathic pain

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...
Reuters

Vertex's trial failure, scrapped study cloud pain drug push; shares slump

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...
STAT

Vertex next-generation pain candidate fails Phase 2 trial

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Yahoo Finance

Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...